News Category
NanoViricides reported fiscal 2026 results, highlighting regulatory approval for Phase II trials of NV-387 in the Democratic Republic of Congo and FDA...
NanoViricides has launched patient enrollment and dosing in a Phase II trial of NV-387 Oral Gummies for Bundibugyo Ebolavirus and other Ebola viruses ...
Vinhomes is scaling its integrated township model beyond Vietnam to Congo, India, Australia, the Philippines, and Indonesia, betting that Asia's urban...
NanoViricides has registered its Phase II clinical trial for NV-387 Oral Gummies as a treatment for Ebola in the Democratic Republic of Congo, marking...
NanoViricides expects to begin a Phase II clinical trial of its oral antiviral NV-387 for Ebola in the DRC, potentially offering a more accessible tre...
GeoVax highlights its MVA-based hemorrhagic fever vaccine candidates as the Bundibugyo Ebola outbreak in Congo becomes the fastest-growing on record, ...
NanoViricides has received regulatory approval to begin a Phase II trial of its oral antiviral NV-387 for Ebola, potentially offering a more accessibl...
NanoViricides has submitted an application to begin a Phase II trial of its NV-387 Oral Gummies for Bundibugyo ebolavirus in the DRC, where no approve...
NanoViricides has applied to the Democratic Republic of Congo's regulatory agency to begin a Phase II clinical trial of its oral antiviral NV-387 for ...
NanoViricides has received National Ethics Committee approval in the DRC for a Phase II trial of its oral NV-387 gummies against Bundibugyo ebolavirus...
The Democratic Republic of Congo's mining ministry reports that copper and cobalt production remains unaffected by Middle East disruptions, offering s...
NanoViricides reports progress on NV-387, a broad-spectrum oral antiviral candidate for Bundibugyo ebolavirus, with Phase II trial approval pending in...
NanoViricides has shipped NV-387 Oral Gummies to the Democratic Republic of Congo for a Phase II trial against MPox, with potential implications for t...
